Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma
Condition(s):Relapse Multiple MyelomaLast Updated:November 6, 2017Unknown status
Hide Studies Not Open or Pending
Condition(s):Relapse Multiple MyelomaLast Updated:November 6, 2017Unknown status
Condition(s):Alzheimer DiseaseLast Updated:September 13, 2016Unknown status
Condition(s):Primary Ciliary DyskinesiaLast Updated:December 16, 2021Completed
Condition(s):PCDLast Updated:May 15, 2017Completed
Condition(s):Multiple Myeloma; First RelapseLast Updated:July 5, 2023Completed
Condition(s):IntubationLast Updated:June 19, 2012Completed
Condition(s):Primary Ciliary Dyskinesia; Kartagener SyndromeLast Updated:August 10, 2022Completed
Condition(s):Diabetic PolyneuropathyLast Updated:April 20, 2012Unknown status
Condition(s):Primary Ciliary DyskinesiaLast Updated:December 27, 2023Recruiting
Condition(s):Primary Ciliary DyskinesiaLast Updated:May 1, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.